Adagio: FDA Feedback Supports Planned Emergency Use Authorization Submission for COVID Preventive

 FDA Feedback Supports Planned Emergency Use Authorization (EUA) Submission for ADG20 for Prevention of COVID-19; Interim Clinical Data Package from EVADE Prevention Trial to Support EUA Submission Expected in Second Quarter 2022

Enrollment Progressing in ADG20 STAMP Trial for Treatment of COVID-19; Planned Interim Efficacy Analysis Expected in Second Quarter 2022 to Support Potential EUA Submission

https://www.globenewswire.com/news-release/2021/11/15/2334008/0/en/Adagio-Therapeutics-Provides-Update-for-ADG20-COVID-19-Antibody-Program-and-Reports-Third-Quarter-2021-Financial-Results.html